Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Long-Term Deferred Tax: 2012-2025

Historic Long-Term Deferred Tax for Catalyst Pharmaceuticals (CPRX) over the last 5 years, with Sep 2025 value amounting to $48.3 million.

  • Catalyst Pharmaceuticals' Long-Term Deferred Tax fell 0.45% to $48.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.3 million, marking a year-over-year decrease of 0.45%. This contributed to the annual value of $46.0 million for FY2024, which is 25.83% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Long-Term Deferred Tax stood at $48.3 million, which was down 4.83% from $50.7 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Long-Term Deferred Tax registered a high of $50.7 million during Q2 2025, and its lowest value of $18.7 million during Q4 2022.
  • For the 3-year period, Catalyst Pharmaceuticals' Long-Term Deferred Tax averaged around $39.8 million, with its median value being $39.9 million (2024).
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Long-Term Deferred Tax crashed by 30.33% in 2022 and then soared by 95.05% in 2023.
  • Catalyst Pharmaceuticals' Long-Term Deferred Tax (Quarterly) stood at $23.7 million in 2021, then dropped by 20.94% to $18.7 million in 2022, then surged by 95.05% to $36.5 million in 2023, then rose by 25.83% to $46.0 million in 2024, then declined by 0.45% to $48.3 million in 2025.
  • Its last three reported values are $48.3 million in Q3 2025, $50.7 million for Q2 2025, and $48.2 million during Q1 2025.